
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Document Content</title>
    <style>
        body { font-family: Arial, sans-serif; line-height: 1.6; max-width: 900px; margin: auto; padding: 20px; }
        table { border-collapse: collapse; width: 100%; margin-top: 20px; margin-bottom: 20px; }
        th, td { border: 1px solid #cccccc; text-align: left; padding: 8px; font-size: 12px; }
        tr:nth-child(even) { background-color: #f9f9f9; }
        th { background-color: #3366CC; color: white; font-weight: bold; }
        h2 { color: #4F81BD; border-bottom: 2px solid #4F81BD; padding-bottom: 5px;}
        p { margin-block-start: 0.5em; margin-block-end: 0.5em; }
    </style>
</head>
<body>
    <p style="font-size: small; color: grey;"><i>abmd-10k 20170331.htm</i></p>
<p style="font-size: small; color: grey;"><i>Page 57 of 83</i></p>
<p style="font-size: small; color: grey;"><i>ABIOMED_10k_057.pdf</i></p>
<p>ABIOMED, INC. AND SUBSIDIARIES Consolidated Balance Sheets (in thousands, except share data)</p>

<table>
	<tr>
		<th></th>
		<th>March 31, 2017</th>
		<th>March 31, 2016</th>
	</tr>
	<tr>
		<td>ASSETS</td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Current assets:</td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Cash and cash equivalents</td>
		<td>$ 39,040</td>
		<td>$ 48,231</td>
	</tr>
	<tr>
		<td>Short-term marketable securities</td>
		<td>190,908</td>
		<td>163,822</td>
	</tr>
	<tr>
		<td>Accounts receivable, net</td>
		<td>54,055</td>
		<td>42,821</td>
	</tr>
	<tr>
		<td>Inventories</td>
		<td>34,931</td>
		<td>26,740</td>
	</tr>
	<tr>
		<td>Prepaid expenses and other current assets</td>
		<td>8,024</td>
		<td>6,778</td>
	</tr>
	<tr>
		<td>Total current assets</td>
		<td>326,958</td>
		<td>288,392</td>
	</tr>
	<tr>
		<td>Long-term marketable securities</td>
		<td>47,143</td>
		<td>1,000</td>
	</tr>
	<tr>
		<td>Property and equipment, net</td>
		<td>87,777</td>
		<td>23,184</td>
	</tr>
	<tr>
		<td>Goodwill</td>
		<td>31,045</td>
		<td>33,003</td>
	</tr>
	<tr>
		<td>In-process research and development</td>
		<td>14,482</td>
		<td>15,396</td>
	</tr>
	<tr>
		<td>Long-term deferred tax assets, net</td>
		<td>34,723</td>
		<td>58,534</td>
	</tr>
	<tr>
		<td>Other assets</td>
		<td>8,286</td>
		<td>4,422</td>
	</tr>
	<tr>
		<td>Total assets</td>
		<td>$ 550,414</td>
		<td>$ 423,931</td>
	</tr>
	<tr>
		<td>LIABILITIES AND STOCKHOLDERS&#x27; EQUITY</td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Current liabilities:</td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Accounts payable</td>
		<td>$ 20,620</td>
		<td>$ 9,381</td>
	</tr>
	<tr>
		<td>Accrued expenses and other liabilities</td>
		<td>37,703</td>
		<td>28,382</td>
	</tr>
	<tr>
		<td>Deferred revenue</td>
		<td>10,495</td>
		<td>8,778</td>
	</tr>
	<tr>
		<td>Current portion of capital lease obligation</td>
		<td>799</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Total current liabilities</td>
		<td>69,617</td>
		<td>46,541</td>
	</tr>
	<tr>
		<td>Other long-term liabilities</td>
		<td>3,251</td>
		<td>220</td>
	</tr>
	<tr>
		<td>Contingent consideration</td>
		<td>9,153</td>
		<td>7,563</td>
	</tr>
	<tr>
		<td>Long-term deferred tax liabilities</td>
		<td>783</td>
		<td>832</td>
	</tr>
	<tr>
		<td>Capital lease obligation, net of current portion</td>
		<td>15,539</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Total liabilities</td>
		<td>98,343</td>
		<td>55,156</td>
	</tr>
	<tr>
		<td>Commitments and contingencies (Note 11)</td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Stockholders&#x27; equity:</td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Class B Preferred Stock, $.01 par value</td>
		<td>—</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Authorized - 1,000,000 shares; Issued and outstanding - none</td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Common stock, $.01 par value</td>
		<td>437</td>
		<td>426</td>
	</tr>
	<tr>
		<td>Authorized - 100,000,000 shares; Issued - 45,249,281 shares at March 31, 2017 and 43,973,119 shares at March 31, 2016;</td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Outstanding - 43,673,286 shares at March 31, 2017 and 42,596,228 shares at March 31, 2016</td>
		<td rowspan="2">565,962</td>
		<td></td>
	</tr>
	<tr>
		<td>Additional paid in capital</td>
		<td>508,624</td>
	</tr>
	<tr>
		<td>Accumulated deficit</td>
		<td>(46,959)</td>
		<td>(99,075)</td>
	</tr>
	<tr>
		<td>Treasury stock at cost - 1,575,995 shares at March 31, 2017 and 1,376,891 shares at March 31, 2016</td>
		<td>(46,763)</td>
		<td>(26,660)</td>
	</tr>
	<tr>
		<td>Accumulated other comprehensive loss</td>
		<td>(20,606)</td>
		<td>(14,540)</td>
	</tr>
	<tr>
		<td>Total stockholders&#x27; equity</td>
		<td>452,071</td>
		<td>368,775</td>
	</tr>
	<tr>
		<td>Total liabilities and stockholders&#x27; equity</td>
		<td>$ 550,414</td>
		<td>$ 423,931</td>
	</tr>
</table>
<p>The accompanying notes are an integral part of the consolidated financial statements.</p>
<p style="font-size: small; color: grey;"><i>F-3</i></p>
<p style="font-size: small; color: grey;"><i>file://usmdcvdi003.us.kworld.kpmg.com/GDC_Ops/Operations/Gayathri%20Krishnan/RPA%20Phase%20II/Kiran/HealthCare/ ... 7/23/2018</i></p>

</body>
</html>
